Latest Development Pipeline News

Actinogen Medical has received an additional $1.87 million R&D tax incentive rebate, bringing its total FY 2025 rebate to $7.36 million, while its Alzheimer’s phase 2b/3 trial progresses with promising safety results.

Dexus Industria REIT (DXI) reported robust half-year results with 7.4% like-for-like income growth and near full occupancy, upgrading its FY26 FFO guidance. The REIT is actively recycling capital and progressing a $225 million development pipeline focused on high-quality industrial assets.

Dexus Industria REIT has slightly upgraded its FY26 funds from operations guidance, driven by robust portfolio income growth and strategic acquisitions in key industrial hubs. The REIT’s active management and development pipeline underpin its confidence in delivering secure, growing income.

Dexus Industria REIT reported a 19.3% drop in net profit for H1 FY26 but edged up its full-year FFO guidance, underpinned by strong leasing and a robust development pipeline.

Arena REIT reported a robust half-year performance for HY2026, with net profit rising to $110 million and earnings per security up 5.4%. The company reaffirmed its FY2026 distribution guidance, underpinned by strong rental growth and disciplined capital management.

Arena REIT has reported a robust HY2026 financial performance, with net operating profit rising 9% and statutory net profit surging 202%. The REIT’s active portfolio management and development pipeline underpin its confidence in sustained growth.

Centuria Industrial REIT (ASX – CIP) reported a robust HY26 with strong income growth, portfolio valuation gains, and an upgraded full-year earnings forecast, underpinned by active leasing and strategic capital management.

National Storage REIT delivered robust half-year results with earnings and occupancy gains, while agreeing to a premium acquisition offer from Brookfield-GIC consortium.

Centuria Industrial REIT has reported robust HY26 financial results, underpinned by solid leasing activity, a $75 million valuation gain, and strategic expansion into the booming data centre sector. The REIT reaffirmed its FY26 guidance, signalling confidence in continued earnings growth amid favourable industrial market conditions.

AGL Energy reported a steady half-year performance with flat EBITDA and a slight dip in net profit, underpinned by improved operational metrics and strategic moves including a major telco divestment and renewable investments.

AGL Energy reported a steady first half with flat underlying EBITDA and a narrowed FY26 earnings outlook, while accelerating its renewable projects and forming a strategic partnership with Aussie Broadband.

Argenica Therapeutics has reported a significant increase in its half-year loss to $3.82 million, driven by reduced revenue and higher research and development expenses. The company continues to invest heavily in its neuroprotective drug candidate ARG-007 amid ongoing clinical trials.